Opioids: Intellipharmaceutics' Pursuit Of IV-Only Deterrence Claim May Backfire
US FDA advisory committee may not be comfortable with intravenous abuse-deterrence labeling for Rexista (oxycodone extended-release) when the sponsor has not assessed the impact on other routes of abuse purportedly targeted by the formulation.
You may also be interested in...
Keeping Track: Industry Channels Inner Gottlieb As Commissioner Departs US FDA
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: A Lilly Breast Cancer Approval, A Couple Of CRLs, And A Plethora Of Priority Reviews
The latest drug development news and highlights from our Performance Tracker.
New Opioids: FDA Should Ditch 'Product-Specific Approach,' Science Report Says
FDA-commissioned study recommends agency consider things like off-label use and risks of transition to illicit drugs in opioid approval decisions; opposes restricting market to abuse deterrent formulations.